Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis

Sherko Kümmel, Miguel Martín, J. Abraham et al.|Annals of Oncology|2018

Cited by 3